Please try another search
For the nine months ended 30 September 2017, Sucampo Pharmaceuticals, Inc. revenues increased 13% to $177.4M. Net loss totaled $166.2M vs. income of $3.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Legal, consulting and other professional increase of 74% to $15.6M (expense), Other income, net decrease from $5.2M (income) to $948K (expense).
Period Ending: | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Revenue | 61.27 | 59.9 | 56.28 | 73.02 |
Gross Profit | 43.83 | 42.86 | 39.4 | 56.3 |
Operating Income | 21.2 | -175.84 | 10.86 | 19.45 |
Net Income | 10.37 | -181.17 | 4.62 | 15.28 |
Period Ending: | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Assets | 388.14 | 365.08 | 529.2 | 520.85 |
Total Liabilities | 348.51 | 338.74 | 354.89 | 353.75 |
Total Equity | 39.63 | 26.35 | 174.31 | 167.1 |
Period Ending: | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | 50.94 | 56.19 | 45.28 | 8.31 |
Cash From Investing Activities | -175.07 | -170.02 | -0.35 | -1.84 |
Cash From Financing Activities | 0.93 | 0.32 | 0.31 | 70.53 |
Net Change in Cash | -123.27 | -113.57 | 45.17 | 90.02 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review